BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 25012490)

  • 41. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
    Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
    Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
    Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
    Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
    Oler G; Cerutti JM
    Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
    Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
    Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
    Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
    Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
    Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
    Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
    Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
    Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
    PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
    Chou CK; Chen RF; Chou FF; Chang HW; Chen YJ; Lee YF; Yang KD; Cheng JT; Huang CC; Liu RT
    Thyroid; 2010 May; 20(5):489-94. PubMed ID: 20406109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
    Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
    Lee JU; Huang S; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Kim SY; Joung KH; Kim JM; Shong M; Jo YS
    Eur J Endocrinol; 2012 Jul; 167(1):93-101. PubMed ID: 22535643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical implications of the extent of BRAF
    Liu L; Chang JW; Jung SN; Park HS; Oh T; Lim YC; Koo BS
    Oral Oncol; 2016 Nov; 62():72-77. PubMed ID: 27865374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients.
    Moore RF; Sholl AB; Kidd L; Al-Qurayshi Z; Tsumagari K; Emejulu OM; Kholmatov R; Friedlander P; Abd Elmageed ZY; Kandil E
    Ann Surg Oncol; 2016 Sep; 23(9):2883-8. PubMed ID: 27146414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.